XML 61 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration arrangements and concentration of credit risk - CSL Behring and Bristol-Myers Squibb collaboration - Narrative (Details)
$ in Thousands
 12 Months Ended
Dec. 01, 2020
USD ($)
item
Jun. 24, 2020
USD ($)
Dec. 31, 2022
USD ($)
item
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2015
USD ($)
Collaboration arrangements            
Number of collaboration targets | item 4          
License revenues from related party         $ 27,800 $ 75,100
Revenue     $ 106,483 $ 524,002 37,514  
Maximum            
Collaboration arrangements            
Collaboration agreement, additional payments receivable on achievement of commercial milestones     1,300      
CSL Behring collaboration.            
Collaboration arrangements            
Revenue     100,000      
Collaboration arrangement, variable milestone revenue not recorded     75,000      
Upfront cash to receive upon the closing of the agreement   $ 450,000        
Other payments received   12,400        
Accounts receivable     2,200 2,900    
Contract asset     100,000 55,000    
Milestone payments to be received upon achievement   $ 55,000        
Collaboration revenues from related party     $ 55,000      
Number of major European Countries, Variable Milestone Revenue Not Recorded | item     1      
Number of Major European Countries | item     5      
Bristol Myers Squibb            
Collaboration arrangements            
Initial research term     4 years      
License revenues from related parties            
Collaboration arrangements            
Revenue     $ 0 0 32,967  
Collaboration revenues from related parties            
Collaboration arrangements            
Revenue         136  
Collaborative Revenue Including Revenue From Related Party            
Collaboration arrangements            
Revenue     1,800 4,200 200  
Contract manufacturing revenues            
Collaboration arrangements            
Revenue     1,717      
Contract manufacturing revenues | CSL Behring collaboration.            
Collaboration arrangements            
Revenue     $ 2,100      
BMS arrangement            
Collaboration arrangements            
Number of collaboration targets | item     4      
Revenue     $ 1,752 4,176 37,514  
BMS arrangement | CSL Behring collaboration.            
Collaboration arrangements            
Number of collaboration targets | item 4          
Collaboration Agreement, Period From Effective Date Collaboration Targets Can Be Replaced 1 year          
Threshold Number Of New Collaboration Targets In The Field Of Cardiovascular Disease | item 2          
BMS arrangement | Bristol Myers Squibb            
Collaboration arrangements            
Initial research term     4 years      
Number of collaboration targets | item     4      
Collaboration Agreement, Threshold Number Of Collaboration Targets That Can Be Replaced | item 2          
Revenue     $ 1,752 4,176 37,514  
Collaboration Agreement, Threshold Research, Development And Regulatory Milestone Payments Receivable $ 217,000          
BMS arrangement | Bristol Myers Squibb | Maximum            
Collaboration arrangements            
Number of collaboration targets | item 4          
Collaborative revenue | CSL Behring collaboration.            
Collaboration arrangements            
Revenue     3,000 2,400 0  
Collaborative revenue | Bristol Myers Squibb            
Collaboration arrangements            
Upfront cash to receive upon the closing of the agreement         4,400  
Variable Consideration Due       0    
License revenue | CSL Behring collaboration.            
Collaboration arrangements            
Revenue     100,000 $ 517,400 $ 0  
License revenue | Bristol Myers Squibb            
Collaboration arrangements            
Maximum target designation payments to which entitled per agreement     16,500      
Manufacturing Development [Member]            
Collaboration arrangements            
Revenue     $ 50,000